TUSTIN, Calif., Feb. 12 /PRNewswire-FirstCall/ -- AMDL, Inc. , developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that Jade Pharmaceuticals, its wholly-owned subsidiary in China, has set up production and applied for SFDA (China State Food and Drug Administration) approval to market Docetaxel in China. Docetaxel is an anti-cancer drug that interferes with the growth of cancer cells.
“There is an enormous need in China for effective and affordable cancer drugs, with more than 1.6 million new cases of the disease annually,” said Gary Dreher, AMDL CEO. “Docetaxel is extremely useful because it can treat a broad spectrum of cancers, including breast cancer, non-small cell lung cancer, stomach cancer and prostate cancer.” Docetaxel currently generates more than $2 billion (USD) in sales globally at a rate increasing 20 percent annually. This drug currently represents approximately $200 million (USD) in sales in China. The Jade Pharmaceutical sales network is uniquely positioned to take advantage of the significant marketing opportunity in China.
“Docetaxel is currently the most popular anticancer drug in China,” Mr. Dreher said. “We are very pleased that our Chinese subsidiary is now a participant in this crucial market. This product is obviously synergistic to AMDL’s focus of detecting and treating cancer. The recent successes of Jade Pharmaceuticals including the introduction of key new products will be a portion of my presentation at the RedChip Small-Cap Investor Conference on February 12.”
The Conference is available live on the Internet at 1:15 p.m. Pacific at http://www.modavox.com/events/redchip/0207/room1/ and for 90 days after the conference at http://www.redchip.com .
About AMDL
AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at www.amdl.com.
Forward-Looking Statements
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460
AMDL, Inc.
CONTACT: Gary L. Dreher, President & CEO, AMDL, Inc., +1-714-505-4460
